Compare Heron Therapeutics Inc (HRTX) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Linde PLC — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Linde PLC trades at $506.58 (market cap $236.74B). The key difference: Linde PLC is far larger — about 2588.5× Heron Therapeutics Inc's market cap, and Linde PLC pays a 1.25% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | LIN | |
|---|---|---|
Market Cap | $91.46M | $236.74B |
Sector | Health | Basic Materials |
52-Week High | $1.96 | $546.64 |
52-Week Low | $0.39 | $389.38 |
Enterprise Value | $189.36M | $259.10B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Linde (LIN) trades at $513.07, down 1.47% today, with strong fundamentals including 20.44% net income margin and consistent earnings beats. Technical indicators show a bearish trend with support at $509 and resistance at $520. The company maintains robust cash flow from operations of $10.35B and has raised dividends, reflecting financial health.
Outlook remains positive with 89% analyst buy ratings and a $564.80 price target, though valuation ratios are elevated. Risks include rising debt-to-asset ratio (31.63% in 2025) and potential macroeconomic pressures. The stock offers growth potential but requires monitoring of leverage and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
